<DOC>
	<DOCNO>NCT00678613</DOCNO>
	<brief_summary>Cirrhotic patient predispose bacterial infection . A large proportion spontaneous bacterial peritonitis ( SBP ) , mainly cause enteric bacteria.SBP cirrhotic patient associate high mortality rate order 30-80 % per year.It demonstrate cirrhotics ascitic fluid protein concentration le 1gm % susceptible develop SBP virtue low opsonising activity ascitic fluid.Patients liver cirrhosis significant degree imbalance intestinal flora.Translocation intestinal bacteria major mechanism production SBP . Long-term antibiotic ( norfloxacin ) effective prevent SBP cause gram negative bacteria.But problem long-term antibiotic prophylaxis potential development infection antibiotic-resistant bacteria.Further , quinolones effect gram positive bacteria become one important cause SBP . Such experience necessitate need strategy , antibiotic , prevent intestinal bacterial overgrowth , bacterial translocation SBP patient cirrhosis.Probiotics use successfully alter gut flora many clinical condition growth localization non pathogenic bacteria replaces pathogenic bacteria intestine.The probiotic bacteria , among common lactose ferment Lactobacilli , inhibit growth pathogenic bacteria acidify gut lumen , compete nutrient , produce antimicrobial substance . They adhere gut mucosa think prevent bacterial translocation gut . The purpose study determine effectiveness probiotic prevention spontaneous bacterial peritonitis patient cirrhosis low protein ascites already developed episode SBP .</brief_summary>
	<brief_title>Role Probiotics Prevention Spontaneous Bacterial Peritonitis Cirrhotic Patients : A Randomized Placebo Control Trial</brief_title>
	<detailed_description>AIMS : To study effect Probiotics administration reduce incidence first episode SBP among cirrhotics low protein ( &lt; 1 gm/dl ) ascites . To study effect Probiotics administration reduce incidence second episode SBP among cirrhotic already develop least one episode SBP . Study design : Prospective randomize placebo control efficacy study . Inclusion criterion : All patient liver cirrhosis ascites either history prior SBP ascitic fluid protein &lt; 1 gm/dl include study irrespective etiology . Exclusion criterion : - Patients chronically treat antibiotic lactulose past 30 day . - Patients risk factor small intestinal bacterial overgrowth cirrhosis - diabetes mellitus , history abdominal surgery , immunomodulator drug . Alcoholic cirrhotics continue take alcohol . - Patients active recent G.I . bleed ( within prior 7 day ) . - Patients advanced HCC , renal failure portal vein thrombosis Patients primary prophylaxis group randomly allocate receive either Probiotics placebo . While patient secondary prophylaxis group randomize Probiotics norfloxacin . The Probiotics use study VSL # 3 . The control give similar look capsule contain galactose powder.It use form capsule . A total dose 450 billion CFU use . Norfloxacin also use similar look capsule . The drug placebo give one year till end point study mention . Monitoring Each patient test SBP ( Ascitic fluid cell count well culture ) interval every 6 week till end point study.The effect Probiotics gut flora assess objectively jejunal fluid culture analysis baseline 6 month 1 year start treatment . This do representative sample group . Development episode SBP , hepatic encephalopathy variceal bleed noted.All patient prospectively follow date enrollment see primary outcome development SBP . The secondary outcome study development encephalopathy , variceal bleeding , renal failure death patient . End Points : 1. completion one year . 2. development episode SBP . 3 . Death .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Peritonitis</mesh_term>
	<mesh_term>Norfloxacin</mesh_term>
	<criteria>All patient liver cirrhosis ascites either history prior SBP ascitic fluid protein &lt; 1 gm/dl include study irrespective etiology . Patients chronically treat antibiotic ( disturb/alter normal gut flora ) lactulose past 30 day . Patients risk factor small intestinal bacterial overgrowth cirrhosis diabetes mellitus , history abdominal surgery , immunomodulator drug . Alcoholic cirrhotics continue take alcohol . Patients active recent G.I . bleed ( within prior 7 day ) . Patients advance HCC , renal failure portal vein thrombosis .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2008</verification_date>
	<keyword>probiotic</keyword>
	<keyword>cirrhosis</keyword>
	<keyword>prophylaxis</keyword>
	<keyword>cirrhotic</keyword>
	<keyword>patient</keyword>
	<keyword />
	<keyword>ascites</keyword>
	<keyword>use</keyword>
</DOC>